Gastric MALT Lymphoma: Symptoms, Treatment & Prognosis

Gastric MALT lymphoma is a slow-growing cancer of the stomach that, in most cases, starts because of a common bacterial infection: Helicobacter pylori. That connection to an infection makes it unusual among cancers and gives it a treatment path that looks nothing like what most people expect from a lymphoma diagnosis. With appropriate treatment, five-year survival rates consistently exceed 90%, though the condition demands years of follow-up and carries some risks that persist long after remission.

How a Stomach Infection Becomes a Lymphoma

The stomach lining does not normally contain organized immune tissue. When H. pylori takes up residence and refuses to leave, the immune system builds it. The bacterium’s persistent presence triggers chronic inflammation, pulling immune cells into the gastric lining and forming clusters of lymphoid tissue that would not otherwise exist there. This is the “MALT” in the name: mucosa-associated lymphoid tissue, created where none belonged.

Inside that new lymphoid tissue, B cells proliferate under continuous stimulation from H. pylori-specific helper T cells. The lymphoma cells resemble memory B cells still responsive to signals from those T cells, and early on, their growth depends entirely on this immune stimulation.

¹ Over time, reactive oxygen species produced by neutrophils and bacterial enzymes cause DNA damage in the constantly dividing B cells, allowing genetic mutations to accumulate and eventually pushing a clone of cells toward true malignancy.²

This is why gastric MALT lymphoma is considered one of the clearest examples of infection-driven cancer in humans.³ In a small number of cases, other related bacteria can drive the same process. Non-H. pylori Helicobacter species have been linked to gastric MALT lymphoma as well.⁴

Symptoms That Mimic Ordinary Stomach Problems

One of the frustrating aspects of gastric MALT lymphoma is that it rarely announces itself. Symptoms range from vague indigestion to more worrying signs like nausea, weight loss, or upper abdominal discomfort, but none of them point specifically to lymphoma.⁵ Many people experience symptoms indistinguishable from garden-variety gastritis or peptic ulcer disease: a burning or gnawing feeling in the upper stomach, bloating, early fullness after eating, or occasional nausea.

Because of this overlap, clinical suspicion and diagnosis are often challenging. Conventional endoscopic findings may not look dramatically abnormal either, which means the condition can be missed on routine exams if the endoscopist is not specifically looking for it.⁶ In practice, many gastric MALT lymphomas are discovered incidentally during endoscopy for longstanding dyspepsia, or when biopsies taken during a routine H. pylori workup come back with unexpected findings.

Getting the Diagnosis Right

Diagnosing gastric MALT lymphoma requires tissue. Biopsy during endoscopy is the primary test, but false-negative results are a real concern; guidelines recommend collecting multiple samples from both normal-appearing and abnormal areas of the stomach to avoid missing a patchy tumor.⁷ On the pathology side, distinguishing MALT lymphoma from chronic gastritis with reactive lymphoid tissue can be genuinely difficult even for experienced pathologists. Specialized immunohistochemistry markers help separate the two conditions.⁸

Once the diagnosis is confirmed, staging determines how far the lymphoma has spread. Endoscopic ultrasound is used to assess how deeply the tumor has invaded the stomach wall and whether perigastric lymph nodes are involved. The standard staging framework, known as the Lugano system, was designed specifically for gastrointestinal lymphomas and examines local spread to neighboring structures.⁹ CT scans or PET scans may also be performed to rule out disease beyond the stomach.

Why Genetic Changes in the Tumor Matter for Treatment

Not all gastric MALT lymphomas behave the same way, and a key dividing line involves specific chromosomal rearrangements inside the tumor cells. The most clinically important is a translocation called t(11;18), which fuses two genes and produces a protein that permanently activates a cell-survival pathway called NF-κB.¹⁰ This matters because tumors carrying t(11;18) have essentially hardwired their own growth signals and no longer depend on H. pylori-driven immune stimulation to keep proliferating.¹¹

The practical consequence is that tumors with this translocation rarely respond to antibiotic therapy alone. Knowing the tumor’s genetic profile up front helps clinicians decide whether to try antibiotics first or move directly to radiation or chemotherapy.

First-Line Treatment: Antibiotics Against Cancer

For most patients with early-stage gastric MALT lymphoma and confirmed H. pylori infection, the first treatment is not chemotherapy or radiation. It is a course of antibiotics to eradicate the bacterium. This is the defining feature of gastric MALT lymphoma as a cancer: remove the infection that drives it, and the tumor often disappears on its own.

Remission rates after successful H. pylori eradication are consistently high. In one study of 99 patients, complete remission was achieved in about 85%, with a median time to remission of three months.¹² A larger analysis of over 340 patients found a complete remission rate of about 82%, though the median time to remission was longer at roughly ten months.¹³ Another retrospective study of 105 patients reported histological regression in 76%.¹⁴

These numbers vary somewhat across studies, but the overall picture is clear: antibiotics alone cure the majority of early-stage cases. Patients need to understand, however, that remission does not always happen quickly. It can take a year or more for the lymphoma to fully regress, and repeated biopsies during that waiting period are part of the process. Deciding too quickly that antibiotics have failed and moving to the next treatment can mean subjecting a patient to unnecessary radiation or chemotherapy.

The response rate is notably lower in patients who test negative for H. pylori. In the same large analysis, H. pylori-negative patients still achieved remission after antibiotic therapy in about 57% of cases, compared with roughly 85% of infected patients.¹³ That 57% figure is surprising and suggests that some H. pylori-negative cases may involve infection that was missed on testing, or that the antibiotics have an immunomodulatory effect beyond killing bacteria. It also means that guidelines recommend trying eradication therapy even in patients who appear H. pylori-negative.

Tumor location within the stomach also seems to play a role. Disease in the lower (distal) portion of the stomach responds more readily to eradication therapy than disease in the upper (proximal) stomach.¹² More advanced stages also respond less well; one series found that only about 30% of patients with stage II disease achieved complete remission from H. pylori eradication alone.

When Antibiotics Are Not Enough

For patients whose tumors do not respond to eradication therapy, or who carry resistance markers like the t(11;18) translocation, radiation therapy is the usual next step for localized disease. A moderate dose of around 30 Gy delivered to the stomach achieves high cure rates with generally manageable side effects.¹⁵ Radiation works well even in patients who were never infected with H. pylori or who failed antibiotic therapy.¹⁶

Relapse after radiation is uncommon, though tumor location matters here too. In a study of 145 patients treated with radiation, the five-year relapse-free survival was about 99% when the dominant tumor was in the gastric body, but dropped to roughly 82% when it was located elsewhere in the stomach.¹⁷

For patients with more advanced or disseminated disease, systemic therapy enters the picture. Combinations of rituximab with chemotherapy agents have shown strong results. In one study, the combination of rituximab with an alkylating agent achieved complete remission in 92% of patients at roughly two years, with a five-year progression-free survival of 89%, both significantly better than either agent used alone.¹⁸ Another small study using rituximab with a standard chemotherapy combination found a 95% complete response rate and 100% disease-specific survival over nearly five years of follow-up.¹⁹ Toxicity was mostly mild and blood-related, without the gastric bleeding or perforation that might concern patients being treated for a stomach tumor.

The largest trial to date found that combining chlorambucil with rituximab appears to be the most active first-line combination regimen, though other combinations like rituximab-bendamustine also look promising and need longer follow-up.²⁰

Long-Term Outlook

The prognosis for gastric MALT lymphoma is among the most favorable of any lymphoma. Five-year overall survival rates consistently land in the range of 95% to 98%. One large study reported a five-year survival of 97.7% with a continuous remission rate of 88.3%.²¹ At ten years, the story remains encouraging: overall survival is around 75%, but very little of the mortality is actually from the lymphoma itself. In a large retrospective study with a median follow-up of over nine years, lymphoma-specific mortality at ten years was only about 4%, meaning the vast majority of deaths were from unrelated causes like heart disease or other cancers.²²

That said, relapse is not rare. About one in seven patients who achieve complete remission will relapse, typically within the first two years.²³ Most relapses can be successfully retreated, so a relapse does not dramatically change the overall survival picture, but it underscores why ongoing monitoring matters.

The Risk of Transformation to Aggressive Lymphoma

Although gastric MALT lymphoma is indolent by nature, it can occasionally transform into diffuse large B-cell lymphoma (DLBCL), a much more aggressive cancer.²⁴ Molecular studies have confirmed that in the majority of cases where a patient develops DLBCL after a prior MALT lymphoma diagnosis, the two are clonally related. This means the aggressive lymphoma genuinely evolved from the original slow-growing one, rather than being a separate, unrelated cancer.²⁵

Transformation dramatically changes the prognosis and requires more intensive treatment, usually systemic chemotherapy regimens used for DLBCL. The overall risk of transformation is low, but it is one of the reasons gastric MALT lymphoma demands long-term surveillance rather than a clean bill of health after remission.

Why Surveillance Needs to Continue for Years

Even after achieving complete remission, patients with gastric MALT lymphoma face two ongoing risks that justify prolonged monitoring: late recurrence and second cancers.

On the recurrence side, the evidence shows that relapses can occur well beyond the first few years. Research on patients carrying extra copies of the MALT1 gene found that recurrences emerged after a decade, suggesting that endoscopic surveillance may need to continue beyond ten years even in patients who have been in complete remission.²⁶

On the second-cancer front, there is a meaningful increase in the risk of gastric adenocarcinoma, the more common type of stomach cancer. A population-based study found that people with a history of gastric MALT lymphoma had roughly four times the risk of developing gastric adenocarcinoma compared with the general population, with a median latency of five years. The risk was especially elevated among those aged 45 to 64.²⁷ This likely reflects the shared underlying cause: chronic H. pylori infection is a risk factor for both gastric MALT lymphoma and gastric adenocarcinoma, and the mucosal damage it causes does not fully reverse even after the bacterium is eradicated.

The risk extends beyond the stomach. A French study found that the overall rate of second primary cancers of any type was elevated in gastric MALT lymphoma patients, with a standardized incidence ratio of about 1.7 compared to the general population. The risk of gastric cancer specifically was strikingly elevated, more than 16 times the expected rate. Interestingly, the elevated risk of second cancers was concentrated among patients who received chemotherapy or immunotherapy, and was not significantly increased in patients treated with H. pylori eradication alone.²⁸ Whether this reflects the effects of treatment itself or simply the more advanced disease that warranted chemotherapy is not fully clear.

The Emerging Microbiome Angle

The discovery that H. pylori drives gastric MALT lymphoma naturally led researchers to wonder whether other microbes in the stomach play a role, especially in the roughly 10% of cases where H. pylori cannot be detected. Studies comparing the gastric microbiome of H. pylori-negative MALT lymphoma patients to healthy controls have found some intriguing differences. Two bacterial genera, Burkholderia and Sphingomonas, were more abundant in lymphoma patients. Burkholderia produces a protein with structural similarities to a protein found in both H. pylori and H. suis, which has led to speculation that it may trigger a similar lymphoma-promoting process. Meanwhile, two genera considered protective against inflammation, Prevotella and Veillonella, were depleted in lymphoma patients.²⁹

This research is still early-stage and observational, so it cannot establish cause and effect. But it offers a plausible explanation for why eradication therapy sometimes works in H. pylori-negative patients: the antibiotics may be disrupting other bacterial communities that sustain the lymphoma. It also suggests that the stomach’s microbial ecosystem, not just a single bacterium, contributes to whether lymphoid tissue in the stomach stays benign or tips toward malignancy.